{"id":11214,"date":"2022-11-23T08:54:24","date_gmt":"2022-11-23T07:54:24","guid":{"rendered":"https:\/\/staging.ggba.swiss\/la-biopharma-genevoise-obseva-vend-sa-licence-ebopiprant-pour-pres-de-usd-113-millions\/"},"modified":"2023-07-04T13:44:08","modified_gmt":"2023-07-04T11:44:08","slug":"la-biopharma-genevoise-obseva-vend-sa-licence-ebopiprant-pour-pres-de-usd-113-millions","status":"publish","type":"post","link":"https:\/\/staging.ggba.swiss\/fr\/la-biopharma-genevoise-obseva-vend-sa-licence-ebopiprant-pour-pres-de-usd-113-millions\/","title":{"rendered":"La biopharma genevoise ObsEva vend sa licence Ebopiprant pour pr\u00e8s de USD 113 millions"},"content":{"rendered":"\n

ObsEva<\/a>\u00a0est une soci\u00e9t\u00e9 biopharmaceutique qui d\u00e9veloppe et commercialise de nouvelles th\u00e9rapies pour am\u00e9liorer la sant\u00e9 reproductive des femmes et la grossesse. Gr\u00e2ce \u00e0 l’acquisition de licences strat\u00e9giques et au d\u00e9veloppement syst\u00e9matique de nouveaux m\u00e9dicaments, ObsEva a \u00e9tabli un pipeline clinique de stade avanc\u00e9 avec des programmes de d\u00e9veloppement ax\u00e9s sur de nouvelles th\u00e9rapies pour le traitement des fibromes ut\u00e9rins, de l’endom\u00e9triose et du travail pr\u00e9-terme.<\/p>\n

Le m\u00e9dicament candidat de la soci\u00e9t\u00e9, l’ebopiprant<\/a>, est un antagoniste s\u00e9lectif et exp\u00e9rimental des r\u00e9cepteurs de la prostaglandine, administr\u00e9 par voie orale, et \u00e9valu\u00e9 comme traitement potentiel du travail pr\u00e9-terme en r\u00e9duisant l’inflammation et les contractions ut\u00e9rines. La soci\u00e9t\u00e9 genevoise a r\u00e9cemment annonc\u00e9 la vente de tous ses droits sur Ebopiprant \u00e0 XOMA Corporation<\/a>.<\/p>\n

\u00ab La vente du contrat de licence Ebopiprant renforce \u00e0 la fois notre position financi\u00e8re imm\u00e9diate, tout en offrant un potentiel de hausse future pour les actionnaires\u00a0\u00bb, a d\u00e9clar\u00e9 Brian O’Callaghan, CEO d’ObsEva. \u00ab Cette transaction marque l’ach\u00e8vement r\u00e9ussi d’un processus de restructuration par lequel nous avons extrait des \u00e9conomies mat\u00e9rielles par la cession de contrats, rationalis\u00e9 notre structure organisationnelle et restructur\u00e9 notre dette. Avec la r\u00e9ception du paiement initial, nous nous attendons \u00e0 avoir plus d’un an de tr\u00e9sorerie et une position strat\u00e9gique am\u00e9lior\u00e9e, et nous avons l’intention de tourner les ressources de la soci\u00e9t\u00e9 vers nolasiban, un nouvel antagoniste oral des r\u00e9cepteurs de l’ocytocine d\u00e9velopp\u00e9 pour am\u00e9liorer les taux de grossesse clinique et de naissance vivante chez les femmes subissant une f\u00e9condation in vitro, tout en \u00e9valuant \u00e9galement les options strat\u00e9giques pour maximiser la valeur pour les actionnaires. ObsEva conserve les droits commerciaux exclusifs et mondiaux de nolasiban, \u00e0 l’exception de la R\u00e9publique populaire de Chine. \u00bb<\/p>\n

En plus des USD 15 millions re\u00e7us en paiement initial, ObsEva est \u00e9ligible \u00e0 recevoir jusqu’\u00e0 USD 98 millions lors de la r\u00e9alisation de certaines \u00e9tapes de d\u00e9veloppement et de r\u00e9glementation ainsi que de ventes dans le cadre de l’accord de licence de la soci\u00e9t\u00e9 avec Organon pour l’Ebopiprant qui a \u00e9t\u00e9 vendu \u00e0 XOMA dans la transaction. En juillet 2021, ObsEva a accord\u00e9 une licence \u00e0 Organon<\/a> pour les droits mondiaux de d\u00e9veloppement, de fabrication et de commercialisation de l’Ebopiprant.<\/p>\n","protected":false},"excerpt":{"rendered":"

ObsEva, sp\u00e9cialiste de la sant\u00e9 f\u00e9minine et reproductive, a annonc\u00e9 la vente de sa licence pour l’Ebopiprant \u00e0 la soci\u00e9t\u00e9 de biotechnologie californienne Xoma pour un montant pouvant atteindre USD 113 millions.<\/p>\n","protected":false},"author":3,"featured_media":11215,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"mc4wp_mailchimp_campaign":[]},"categories":[843,842],"tags":[1022,1068,1069],"acf":[],"yoast_head":"\nLa biopharma genevoise ObsEva vend sa licence Ebopiprant pour pr\u00e8s de USD 113 millions - Greater Geneva Bern area<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La biopharma genevoise ObsEva vend sa licence Ebopiprant pour pr\u00e8s de USD 113 millions - Greater Geneva Bern area\" \/>\n<meta property=\"og:description\" content=\"ObsEva, sp\u00e9cialiste de la sant\u00e9 f\u00e9minine et reproductive, a annonc\u00e9 la vente de sa licence pour l'Ebopiprant \u00e0 la soci\u00e9t\u00e9 de biotechnologie californienne Xoma pour un montant pouvant atteindre USD 113 millions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/staging.ggba.swiss\/fr\/la-biopharma-genevoise-obseva-vend-sa-licence-ebopiprant-pour-pres-de-usd-113-millions\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-23T07:54:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-04T11:44:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-Baby-630x380-1-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"630\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"mathieu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"mathieu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/staging.ggba.swiss\/fr\/la-biopharma-genevoise-obseva-vend-sa-licence-ebopiprant-pour-pres-de-usd-113-millions\/\",\"url\":\"https:\/\/staging.ggba.swiss\/fr\/la-biopharma-genevoise-obseva-vend-sa-licence-ebopiprant-pour-pres-de-usd-113-millions\/\",\"name\":\"La biopharma genevoise ObsEva vend sa licence Ebopiprant pour pr\u00e8s de USD 113 millions - Greater Geneva Bern area\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"datePublished\":\"2022-11-23T07:54:24+00:00\",\"dateModified\":\"2023-07-04T11:44:08+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/8e5f085a3c4b5b152358afca41905511\"},\"breadcrumb\":{\"@id\":\"https:\/\/staging.ggba.swiss\/fr\/la-biopharma-genevoise-obseva-vend-sa-licence-ebopiprant-pour-pres-de-usd-113-millions\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/staging.ggba.swiss\/fr\/la-biopharma-genevoise-obseva-vend-sa-licence-ebopiprant-pour-pres-de-usd-113-millions\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/staging.ggba.swiss\/fr\/la-biopharma-genevoise-obseva-vend-sa-licence-ebopiprant-pour-pres-de-usd-113-millions\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/staging.ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La biopharma genevoise ObsEva vend sa licence Ebopiprant pour pr\u00e8s de USD 113 millions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/8e5f085a3c4b5b152358afca41905511\",\"name\":\"mathieu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/066e0c4bb04d41ae36e3347b25b925cc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/066e0c4bb04d41ae36e3347b25b925cc?s=96&d=mm&r=g\",\"caption\":\"mathieu\"},\"url\":\"https:\/\/staging.ggba.swiss\/fr\/author\/mathieu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La biopharma genevoise ObsEva vend sa licence Ebopiprant pour pr\u00e8s de USD 113 millions - Greater Geneva Bern area","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"La biopharma genevoise ObsEva vend sa licence Ebopiprant pour pr\u00e8s de USD 113 millions - Greater Geneva Bern area","og_description":"ObsEva, sp\u00e9cialiste de la sant\u00e9 f\u00e9minine et reproductive, a annonc\u00e9 la vente de sa licence pour l'Ebopiprant \u00e0 la soci\u00e9t\u00e9 de biotechnologie californienne Xoma pour un montant pouvant atteindre USD 113 millions.","og_url":"https:\/\/staging.ggba.swiss\/fr\/la-biopharma-genevoise-obseva-vend-sa-licence-ebopiprant-pour-pres-de-usd-113-millions\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2022-11-23T07:54:24+00:00","article_modified_time":"2023-07-04T11:44:08+00:00","og_image":[{"width":630,"height":380,"url":"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-Baby-630x380-1-2.jpg","type":"image\/jpeg"}],"author":"mathieu","twitter_card":"summary_large_image","twitter_misc":{"Written by":"mathieu","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/staging.ggba.swiss\/fr\/la-biopharma-genevoise-obseva-vend-sa-licence-ebopiprant-pour-pres-de-usd-113-millions\/","url":"https:\/\/staging.ggba.swiss\/fr\/la-biopharma-genevoise-obseva-vend-sa-licence-ebopiprant-pour-pres-de-usd-113-millions\/","name":"La biopharma genevoise ObsEva vend sa licence Ebopiprant pour pr\u00e8s de USD 113 millions - Greater Geneva Bern area","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"datePublished":"2022-11-23T07:54:24+00:00","dateModified":"2023-07-04T11:44:08+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/8e5f085a3c4b5b152358afca41905511"},"breadcrumb":{"@id":"https:\/\/staging.ggba.swiss\/fr\/la-biopharma-genevoise-obseva-vend-sa-licence-ebopiprant-pour-pres-de-usd-113-millions\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/staging.ggba.swiss\/fr\/la-biopharma-genevoise-obseva-vend-sa-licence-ebopiprant-pour-pres-de-usd-113-millions\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/staging.ggba.swiss\/fr\/la-biopharma-genevoise-obseva-vend-sa-licence-ebopiprant-pour-pres-de-usd-113-millions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/staging.ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"La biopharma genevoise ObsEva vend sa licence Ebopiprant pour pr\u00e8s de USD 113 millions"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/8e5f085a3c4b5b152358afca41905511","name":"mathieu","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/066e0c4bb04d41ae36e3347b25b925cc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/066e0c4bb04d41ae36e3347b25b925cc?s=96&d=mm&r=g","caption":"mathieu"},"url":"https:\/\/staging.ggba.swiss\/fr\/author\/mathieu\/"}]}},"_links":{"self":[{"href":"https:\/\/staging.ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/11214"}],"collection":[{"href":"https:\/\/staging.ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging.ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging.ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=11214"}],"version-history":[{"count":1,"href":"https:\/\/staging.ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/11214\/revisions"}],"predecessor-version":[{"id":18278,"href":"https:\/\/staging.ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/11214\/revisions\/18278"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/staging.ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/11215"}],"wp:attachment":[{"href":"https:\/\/staging.ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=11214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging.ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=11214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging.ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=11214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}